This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendInsider Trades About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Get CYCC alerts:Sign Up Key Stats Today's Range$6.37▼$6.3750-Day Range$6.36▼$9.2852-Week Range$0.22▼$19.87VolumeN/AAverage Volume3.54 million shsMarket Capitalization$14.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapies that target key mechanisms of cell division. Founded in 1996, the company has built a pipeline of experimental small-molecule inhibitors designed to disrupt the activity of cyclin-dependent kinases (CDKs) and other cell cycle regulators. These targeted agents are intended to selectively halt the proliferation of tumor cells while minimizing effects on healthy tissue. The company’s most advanced programs include fadraciclib (formerly CYC065), an oral CDK2/9 inhibitor in Phase 1/2 studies for advanced solid tumors and hematologic malignancies, and CYC140, a novel allosteric inhibitor of aurora kinases under early clinical evaluation. Cyclacel’s research and development efforts leverage in-house discovery platforms as well as strategic collaborations with academic institutions and contract research organizations. This collaborative model supports rapid translation of laboratory findings into clinical candidates. Cyclacel is headquartered in Berkeley Heights, New Jersey, with additional research operations in Dundee, Scotland, reflecting its UK-US footprint. Over the years, the company has advanced multiple compounds into human trials, demonstrating its ability to move promising molecules through preclinical stages. Under its experienced management team, Cyclacel continues to explore combination regimens and biomarker-driven approaches to enhance the therapeutic potential of its pipeline agents for patients with hard-to-treat cancers.AI Generated. May Contain Errors. Read More Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYCC Stock News HeadlinesCyclacel Pharmaceuticals Implements Reverse Stock Split in JulyAugust 14, 2025 | msn.comCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateAugust 13, 2025 | globenewswire.comThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of Americans use Gold IRAs to diversify retirement savings amid rising national debt. The free 2026 Beginner's Guide to Gold IRAs covers top advantages, penalty free 401k rollovers, and simple steps to get started.September 14 at 1:00 AM | Goldco Direct, LLC (Ad)CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIBAugust 4, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITYJuly 16, 2025 | finance.yahoo.comCyclacel stock dips after trimming 270% surge amid volatility concernsJuly 16, 2025 | msn.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15, 2025 | benzinga.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15, 2025 | benzinga.comSee More Headlines CYCC Stock Analysis - Frequently Asked Questions How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($72.00) by $71.02. When did Cyclacel Pharmaceuticals' stock split? Cyclacel Pharmaceuticals shares reverse split before market open on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET). Company Calendar Last Earnings8/13/2025Today9/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:CYCC CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees14Year Founded1992Profitability EPS (Trailing Twelve Months)($839.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.21 million Net MarginsN/A Pretax Margin-54,220.00% Return on Equity-723.64% Return on Assets-145.51% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio5.77 Sales & Book Value Annual Sales$40 thousand Price / Sales356.44 Cash FlowN/A Price / Cash FlowN/A Book Value($58.87) per share Price / Book-0.11Miscellaneous Outstanding Shares2,240,000Free Float1,093,000Market Cap$14.26 million OptionableOptionable Beta0.15 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CYCC) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
